MX348380B - Pruducto inmunogénico para usarse en vacunas. - Google Patents

Pruducto inmunogénico para usarse en vacunas.

Info

Publication number
MX348380B
MX348380B MX2013011675A MX2013011675A MX348380B MX 348380 B MX348380 B MX 348380B MX 2013011675 A MX2013011675 A MX 2013011675A MX 2013011675 A MX2013011675 A MX 2013011675A MX 348380 B MX348380 B MX 348380B
Authority
MX
Mexico
Prior art keywords
treating
related conditions
ifnalpha
ifna
induce
Prior art date
Application number
MX2013011675A
Other languages
English (en)
Other versions
MX2013011675A (es
Inventor
Grouard-Vogel Geraldine
Dhellin Olivier
Roucairol Camille
Fanget Bernard
Vandepapelière Pierre
Original Assignee
Neovacs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11305408A external-priority patent/EP2508197A1/en
Application filed by Neovacs filed Critical Neovacs
Publication of MX2013011675A publication Critical patent/MX2013011675A/es
Publication of MX348380B publication Critical patent/MX348380B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)

Abstract

La presente invención se refiere a un producto inmunogénico que comprende IFNa acoplado a Hemocianina de lapa de ojo de cerradura (KLH), para usarse en el tratamiento de una condición relacionada con IFNa, en donde dicho producto inmunogénico esta adaptado para ser administrado en una cantidad terapéuticamente efectiva de al menos 60 mcg de producto inmunogénico por administración, la relación IFNa/KLH está en el rango de 0.06 a 0.6. y la condición relacionada con IFNa se selecciona del grupo conistente en lupus eritematoso sistémico, artritis reumatoide, escleroderma, síndrome de Sjögren, vasculitis, VIH, diabetes tipo I, tiroiditis autoinmune y miositis.
MX2013011675A 2011-04-07 2012-04-04 Pruducto inmunogénico para usarse en vacunas. MX348380B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161472854P 2011-04-07 2011-04-07
EP11305408A EP2508197A1 (en) 2011-04-07 2011-04-07 Method for treating IFNalpha related conditions
EP11188125 2011-11-07
PCT/EP2012/056238 WO2012136739A1 (en) 2011-04-07 2012-04-04 Method for treating ifnalpha related conditions

Publications (2)

Publication Number Publication Date
MX2013011675A MX2013011675A (es) 2014-01-31
MX348380B true MX348380B (es) 2017-06-09

Family

ID=46968636

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011675A MX348380B (es) 2011-04-07 2012-04-04 Pruducto inmunogénico para usarse en vacunas.

Country Status (16)

Country Link
US (2) US9993565B2 (es)
EP (2) EP2694094B1 (es)
JP (2) JP6335778B2 (es)
KR (1) KR102017905B1 (es)
CN (1) CN103608031B (es)
AU (1) AU2012238643B2 (es)
BR (1) BR112013025892B1 (es)
CA (1) CA2832260C (es)
DK (1) DK2694094T3 (es)
ES (1) ES2644824T3 (es)
IL (1) IL228744A0 (es)
MX (1) MX348380B (es)
PL (1) PL2694094T3 (es)
PT (1) PT2694094T (es)
RU (1) RU2639135C2 (es)
WO (1) WO2012136739A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2694094B1 (en) * 2011-04-07 2017-08-16 Neovacs METHOD FOR TREATING IFNalpha RELATED CONDITIONS
WO2017009863A1 (en) * 2015-07-14 2017-01-19 Indian Immunologicals Limited A scalable, low variation and efficient method for purification of diphtheria toxoid and uses thereof
EP3574915A1 (en) * 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
ES2039229T3 (es) 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US6277828B1 (en) 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
FR2812813B1 (fr) 2000-08-09 2004-11-26 Neovacs Utilisation d'immunogenes pour traiter ou prevenir au sein des tumeurs malignes les dereglements immunitaires induits par des facteurs extracellulaires
FR2844514B1 (fr) 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
FR2859725B1 (fr) * 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
CN101381728A (zh) * 2008-07-01 2009-03-11 丁国庆 人干扰素α-2b重组卡介苗及其构建方法和鉴定方法
EP2694094B1 (en) * 2011-04-07 2017-08-16 Neovacs METHOD FOR TREATING IFNalpha RELATED CONDITIONS

Also Published As

Publication number Publication date
AU2012238643B2 (en) 2017-04-13
IL228744A0 (en) 2013-12-31
AU2012238643A1 (en) 2013-10-24
MX2013011675A (es) 2014-01-31
CA2832260C (en) 2021-06-22
JP2014510126A (ja) 2014-04-24
PL2694094T3 (pl) 2018-01-31
RU2639135C2 (ru) 2017-12-19
CA2832260A1 (en) 2012-10-11
KR102017905B1 (ko) 2019-09-03
CN103608031B (zh) 2016-08-17
DK2694094T3 (da) 2017-11-13
PT2694094T (pt) 2017-11-06
RU2013144441A (ru) 2015-05-20
BR112013025892B1 (pt) 2021-01-19
US20140023617A1 (en) 2014-01-23
EP2694094A1 (en) 2014-02-12
EP3272355A1 (en) 2018-01-24
US9993565B2 (en) 2018-06-12
BR112013025892A2 (pt) 2016-09-06
JP6335778B2 (ja) 2018-05-30
US20180207288A1 (en) 2018-07-26
WO2012136739A1 (en) 2012-10-11
ES2644824T3 (es) 2017-11-30
KR20140053879A (ko) 2014-05-08
CN103608031A (zh) 2014-02-26
JP2017105812A (ja) 2017-06-15
EP2694094B1 (en) 2017-08-16

Similar Documents

Publication Publication Date Title
HRP20150935T1 (en) Conjugation process of bacterial polysaccharides to carrier proteins
EP2694660A4 (en) EFFICIENT IN VIVO PROTEIN EXPRESSION USING MODIFIED RNA (MOD RNA)
MX341578B (es) Tratamiento de la osteoartritis y del dolor.
HK1199460A1 (en) Antigen binding protein and its use as addressing product for the treatment of cancer
EP2850201A4 (en) Site-specific labeling and targeted administration of proteins for the treatment of cancer
ZA201408916B (en) Novel process for preparation of antibody conjugates and novel antibody conjugates
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
SI2683408T1 (sl) Postopek za konjugacijo bakterijskega antigena na nosilni protein
SI2718265T1 (sl) Postopek za pripravo estrov in amidov ((3-hidroksipiridin-2-karboksil)amino) alkanojske kisline
MX2011010955A (es) Terapia complementaria contra el cancer.
ZA201108291B (en) Protein product and process for preparing injectable protein product
ZA201108290B (en) Protein product and process for making injectable protein product
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
PL2661180T3 (pl) Mieszanka zawierająca ciepłochwiejne białka mleka i sposób jej przygotowania
EP2726100A4 (en) ANTI-ERBB3 ANTIBODY IN COMBINATION WITH PACLITAXEL FOR THE TREATMENT OF GYNECOLOGICAL CANCERS
IL206528A (en) Process for making concentrated soy protein
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
EP2808388A4 (en) EXPRESSION VECTOR AND PROCESS FOR PRODUCING PROTEINS
MX348380B (es) Pruducto inmunogénico para usarse en vacunas.
EP2737062A4 (en) BY NON-INFRARED LIGHT ACTIVATED PROTEINS
EP2757872A4 (en) TOBACCO WITH REDUCED QUANTITIES OF AMINO ACIDS AND METHODS OF MAKING SUCH LINES
IL229383A0 (en) A process for purifying protein with a low acidity level
EG26169A (en) A gene-treated compound for use as a protein carrier
RO127733B8 (ro) Produs de origine naturală pentru tratament oftalmic şi procedeu de obţinere
EP2876159A4 (en) MOLECULAR ENGINEERING PROCESS FOR THE IN VITRO EVOLUTION OF A MEMBRANE PROTEIN

Legal Events

Date Code Title Description
FG Grant or registration